<DOC>
	<DOCNO>NCT02183636</DOCNO>
	<brief_summary>Determination relative bioavailability 2 different formulation 5 mg linagliptin ( BI 1356 ) /45 mg pioglitazone fix dose combination ( FDC ) tablet , formulation C5 formulation C8 , compare mono-components linagliptin pioglitazone administer together</brief_summary>
	<brief_title>Relative Bioavailability Two Fixed Dose Combination Tablets Linagliptin/Pioglitazone Compared With Single Linagliptin Pioglitazone Tablets Administered Together Healthy Male Female Subjects</brief_title>
	<detailed_description />
	<mesh_term>Pioglitazone</mesh_term>
	<mesh_term>Linagliptin</mesh_term>
	<criteria>Healthy male female subject accord follow criterion : base upon complete medical history , include physical examination , vital sign ( BP , PR ) , 12lead ECG , clinical laboratory test Age ≥18 ≤55 year Body mass index ( BMI ) ≥18.5 ≤29.9 kg/m2 Signed date write informed consent prior admission study , accordance GCP local legislation Any finding medical examination ( include BP , PR , ECG ) deviate normal clinical relevance Any evidence clinically relevant concomitant disease Gastrointestinal , hepatic , renal , respiratory , cardiovascular , metabolic , immunological hormonal disorder Surgery gastrointestinal tract ( except appendectomy ) Diseases central nervous system ( epilepsy ) , psychiatric disorder , neurological disorder History relevant orthostatic hypotension , faint spell , blackout Chronic relevant acute infection History relevant allergy/hypersensitivity ( include allergy drug excipients ) Intake drug long halflife ( &gt; 24 h ) within least 1 month less 10 halflives respective drug prior administration trial Use drug might reasonably influence result trial base knowledge time protocol preparation within 10 day prior administration trial Participation another trial investigational drug within 2 month prior administration trial Smoker ( &gt; 10 cigarette &gt; 3 cigar &gt; 3 pipes/day ) Inability refrain smoke trial day Alcohol abuse ( 30 g/day male 20 g/day female ) Drug abuse Blood donation ( 100 mL within 4 week prior administration trial ) Excessive physical activity ( within 1 week prior administration trial ) Any laboratory value outside reference range clinical relevance Inability comply dietary regimen trial site For female subject : Pregnancy positive pregnancy test , plan become pregnant study , within 1 month study completion lactation period No adequate contraception study 1 month study completion , i.e . implant , injectables , combine oral contraceptive , intrauterine device , sexual abstinence ( least 1 month enrolment ) , vasectomised partner ( vasectomy perform least 1 year prior enrolment ) , surgical sterilisation ( include hysterectomy ) . Females vasectomise partner , sexually abstinent , surgically sterile ask additionally use barrier contraception method ( i.e . condom , diaphragm spermicide ) For male subject : Male subject agree minimise risk female partner become pregnant first dose day completion post study medical examination . Acceptable method contraception include barrier contraception medically accept contraceptive method female partner ( intrauterine device spermicide , hormonal contraceptive least 2 month )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>July 2014</verification_date>
</DOC>